{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:30:36Z","timestamp":1774625436883,"version":"3.50.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.genhosppsych.2023.05.003","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T11:21:28Z","timestamp":1683544888000},"page":"185-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study"],"prefix":"10.1016","volume":"83","author":[{"given":"Renata","family":"Alisauskiene","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf","family":"Gjestad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rune A.","family":"Kroken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirik","family":"Kjelby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igne","family":"Sinkeviciute","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farivar","family":"Fathian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Joa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Solveig Kl\u00e6bo","family":"Reitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Rettenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Else-Marie","family":"L\u00f8berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.genhosppsych.2023.05.003_bb0005","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1192\/bjp.bp.107.046375","article-title":"Effects of cannabis use on outcomes of psychotic disorders: systematic review","volume":"193","author":"Zammit","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.genhosppsych.2023.05.003_bb0010","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.schres.2011.04.011","article-title":"The impact of substance use disorders on the course of schizophrenia--a 15-year follow-up study: dual diagnosis over 15 years","volume":"130","author":"Schmidt","year":"2011","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"10.1016\/j.genhosppsych.2023.05.003_bb0015","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.schres.2015.11.016","article-title":"Substance use, medication adherence and outcome one year following a first episode of psychosis","volume":"170","author":"Colizzi","year":"2016","journal-title":"Schizophr Res"},{"issue":"3","key":"10.1016\/j.genhosppsych.2023.05.003_bb0020","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/schbul\/sbu138","article-title":"Mortality in schizophrenia and other psychoses: a 10-year follow-up of the SOP first-episode cohort","volume":"41","author":"Reininghaus","year":"2015","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pscychresns.2018.08.008","article-title":"Abnormalities of fronto-subcortical pathways in schizophrenia and the differential impacts of antipsychotic treatment: a DTI-based tractography study","volume":"280","author":"Leroux","year":"2018","journal-title":"Psychiatry Res Neuroimaging"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnbeh.2011.00001","article-title":"Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light","volume":"5","author":"Paparelli","year":"2011","journal-title":"Front Behav Neurosci"},{"issue":"8","key":"10.1016\/j.genhosppsych.2023.05.003_bb0035","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","article-title":"The nature of dopamine dysfunction in schizophrenia and what this means for treatment","volume":"69","author":"Howes","year":"2012","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"10.1016\/j.genhosppsych.2023.05.003_bb0040","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S2215-0366(20)30341-2","article-title":"Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial","volume":"7","author":"Johnsen","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"10.1016\/j.genhosppsych.2023.05.003_bb0045","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.genhosppsych.2023.05.003_bb0050","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007691-200404000-00020","article-title":"Detection times of drugs of abuse in blood, urine, and oral fluid","volume":"26","author":"Verstraete","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.genhosppsych.2023.05.003_bb0055","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/01.ftd.0000197091.07807.22","article-title":"Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use","volume":"28","author":"Musshoff","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.drugalcdep.2014.08.003","article-title":"Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature","volume":"143","author":"Courtney","year":"2014","journal-title":"Drug Alcohol Depend"},{"issue":"7629","key":"10.1016\/j.genhosppsych.2023.05.003_bb0065","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nature20153","article-title":"The effects of \u0394(9)-tetrahydrocannabinol on the dopamine system","volume":"539","author":"Bloomfield","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.genhosppsych.2023.05.003_bb0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/schbul\/16.1.81","article-title":"Psychotogenic drug use and neuroleptic response","volume":"16","author":"Bowers","year":"1990","journal-title":"Schizophr Bull"},{"issue":"3","key":"10.1016\/j.genhosppsych.2023.05.003_bb0075","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.nmd.0000202575.79453.6e","article-title":"Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study","volume":"194","author":"Swartz","year":"2006","journal-title":"J Nerv Ment Dis"},{"issue":"9","key":"10.1016\/j.genhosppsych.2023.05.003_bb0080","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1176\/ps.62.9.pss6209_1007","article-title":"Substance use disorder among people with first-episode psychosis: a systematic review of course and treatment","volume":"62","author":"Wisdom","year":"2011","journal-title":"Psychiatr Serv"},{"issue":"4","key":"10.1016\/j.genhosppsych.2023.05.003_bb0085","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.cpr.2006.09.004","article-title":"Reasons for increased substance use in psychosis","volume":"27","author":"Gregg","year":"2007","journal-title":"Clin Psychol Rev"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0090","author":"(EMCDDA), E.M.C.f.D.a.D.A"},{"issue":"2","key":"10.1016\/j.genhosppsych.2023.05.003_bb0095","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/0004867414561526","article-title":"Stimulant use disorders in people with psychosis: a meta-analysis of rate and factors affecting variation","volume":"49","author":"Sara","year":"2015","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0100","author":"Crime, U.N.O.o.D.a"},{"issue":"2","key":"10.1016\/j.genhosppsych.2023.05.003_bb0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11920-015-0657-y","article-title":"Cannabis and psychosis: a critical overview of the relationship","volume":"18","author":"Ksir","year":"2016","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0110","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.drugalcdep.2016.01.018","article-title":"The profile of psychiatric symptoms exacerbated by methamphetamine use","volume":"161","author":"McKetin","year":"2016","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.genhosppsych.2023.05.003_bb0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0376-8716(98)00129-X","article-title":"Do hallucinogens cause residual neuropsychological toxicity?","volume":"53","author":"Halpern","year":"1999","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"10.1016\/j.genhosppsych.2023.05.003_bb0120","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction","volume":"57","author":"D'Souza","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"4\u20135","key":"10.1016\/j.genhosppsych.2023.05.003_bb0125","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/08039488.2019.1622152","article-title":"The influence of substance use on the effectiveness of antipsychotic medication: a prospective, pragmatic study","volume":"73","author":"Alisauskiene","year":"2019","journal-title":"Nord J Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.genhosppsych.2023.05.003_bb0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.schres.2007.11.034","article-title":"The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study","volume":"100","author":"Swartz","year":"2008","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.genhosppsych.2023.05.003_bb0135","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1017\/S0033291713000330","article-title":"Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis","volume":"44","author":"Pelayo-Teran","year":"2014","journal-title":"Psychol Med"},{"issue":"2\u20133","key":"10.1016\/j.genhosppsych.2023.05.003_bb0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.schres.2003.08.001","article-title":"First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol","volume":"66","author":"Green","year":"2004","journal-title":"Schizophr Res"},{"issue":"2","key":"10.1016\/j.genhosppsych.2023.05.003_bb0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0376-8716(03)00033-4","article-title":"Single versus multiple drug focus in substance abuse clinical trials research","volume":"70","author":"Rounsaville","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"10.1016\/j.genhosppsych.2023.05.003_bb0150","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.euroneuro.2017.06.011","article-title":"How well do patients with a first episode of schizophrenia respond to antipsychotics: a systematic review and meta-analysis","volume":"27","author":"Zhu","year":"2017","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.genhosppsych.2023.05.003_bb0155","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00213-018-5133-z","article-title":"Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis","volume":"236","author":"Smith","year":"2019","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.genhosppsych.2023.05.003_bb0160","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0165","series-title":"The WHO collaborating centre for drug statistics methodology","author":"Ronning","year":"1982"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jsat.2015.01.008","article-title":"The psychometric properties of the drug use disorders identification test (DUDIT): a review of recent research","volume":"53","author":"Hildebrand","year":"2015","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0175","series-title":"ECDEU assessment manual for psychopharmacology: Rockville","author":"Guy","year":"1976"},{"issue":"1","key":"10.1016\/j.genhosppsych.2023.05.003_bb0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/schbul\/16.1.57","article-title":"Diagnosis of alcohol use disorders in schizophrenia","volume":"16","author":"Drake","year":"1990","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0190","series-title":"DUDIT: The drug use disorders identification test: MANUAL","author":"Bergman","year":"2003"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0195","series-title":"Outcomes assessment in clinical practice","author":"Drake","year":"1996"},{"issue":"1","key":"10.1016\/j.genhosppsych.2023.05.003_bb0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000081413","article-title":"Evaluation of the drug use disorders identification test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample","volume":"11","author":"Berman","year":"2005","journal-title":"Eur Addict Res"},{"issue":"1","key":"10.1016\/j.genhosppsych.2023.05.003_bb0205","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addbeh.2011.07.030","article-title":"Psychometric properties of the drug use disorders identification test (DUDIT) with substance abusers in outpatient and residential treatment","volume":"37","author":"Voluse","year":"2012","journal-title":"Addict Behav"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0215","series-title":"IBM SPSS statistics for windows. Version 26.0","author":"IBM Corp","year":"2019"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0220","series-title":"Mplus 8.5","author":"Muth\u00e9n","year":"2020"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0225","series-title":"Latent curve models: A structural equation perspective","author":"Bollen","year":"2006"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0230","series-title":"Structural equation modeling: Applications using Mplus Wiley series in probability and statistics","author":"Wang","year":"2012"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0235","series-title":"An introduction to multilevel modeling techniques - MLM and SEM approaches using Mplus","author":"Heck","year":"2015"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0240","series-title":"Principles and practice of structural Equation Modeling","author":"Kline","year":"2016"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0245","series-title":"Applied missing data analysis","author":"Enders","year":"2010"},{"issue":"2\u20133","key":"10.1016\/j.genhosppsych.2023.05.003_bb0250","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0920-9964(02)00523-6","article-title":"Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences","volume":"67","author":"Margolese","year":"2004","journal-title":"Schizophr Res"},{"issue":"14","key":"10.1016\/j.genhosppsych.2023.05.003_bb0255","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1017\/S0033291717000976","article-title":"Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes","volume":"47","author":"Ouellet-Plamondon","year":"2017","journal-title":"Psychol Med"},{"issue":"7374","key":"10.1016\/j.genhosppsych.2023.05.003_bb0260","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/bmj.325.7374.1212","article-title":"Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study","volume":"325","author":"Arseneault","year":"2002","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.genhosppsych.2023.05.003_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055821","article-title":"Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings","volume":"8","author":"Batalla","year":"2013","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.genhosppsych.2023.05.003_bb0270","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1017\/S0033291716003172","article-title":"Assessing causality in associations between cannabis use and schizophrenia risk: a two-sample Mendelian randomization study","volume":"47","author":"Gage","year":"2017","journal-title":"Psychol Med"},{"issue":"1","key":"10.1016\/j.genhosppsych.2023.05.003_bb0275","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.schres.2015.11.027","article-title":"Cannabis use is associated with 3years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N=1119)","volume":"170","author":"Helle","year":"2016","journal-title":"Schizophr Res"},{"issue":"6","key":"10.1016\/j.genhosppsych.2023.05.003_bb0280","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/schbul\/sbt181","article-title":"Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users","volume":"40","author":"Di Forti","year":"2014","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0285","first-page":"94","article-title":"An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use","volume":"3","author":"Loberg","year":"2012","journal-title":"Front Psych"},{"key":"10.1016\/j.genhosppsych.2023.05.003_bb0290","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/neuro.09.053.2009","article-title":"Cannabis use and cognition in schizophrenia","volume":"3","author":"Loberg","year":"2009","journal-title":"Front Hum Neurosci"},{"issue":"5","key":"10.1016\/j.genhosppsych.2023.05.003_bb0295","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/0004867414525838","article-title":"Systematic meta-analysis of outcomes associated with psychosis and co-morbid substance use","volume":"48","author":"Large","year":"2014","journal-title":"Aust N Z J Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.genhosppsych.2023.05.003_bb0300","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0920-9964(03)00188-9","article-title":"Early life stress and PTSD symptoms in patients with comorbid schizophrenia and substance abuse","volume":"69","author":"Scheller-Gilkey","year":"2004","journal-title":"Schizophr Res"},{"issue":"4","key":"10.1016\/j.genhosppsych.2023.05.003_bb0305","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.genhosppsych.2023.05.003_bb0310","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.tips.2008.03.009","article-title":"Antipsychotic drug action: antagonism, inverse agonism or partial agonism","volume":"29","author":"Strange","year":"2008","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.genhosppsych.2023.05.003_bb0315","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity","volume":"280","author":"Schoemaker","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.genhosppsych.2023.05.003_bb0320","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.pnpbp.2003.09.006","article-title":"Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality","volume":"27","author":"Moller","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.genhosppsych.2023.05.003_bb0325","first-page":"138","article-title":"Treatment with amisulpride of addicted patients to psychoactive substances and psychotic symptoms","volume":"38","author":"Manez","year":"2010","journal-title":"Actas Esp Psiquiatr"},{"issue":"6","key":"10.1016\/j.genhosppsych.2023.05.003_bb0330","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/070674370805300610","article-title":"Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial","volume":"53","author":"van Nimwegen","year":"2008","journal-title":"Can J Psychiatry"},{"issue":"3","key":"10.1016\/j.genhosppsych.2023.05.003_bb0335","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0376-8716(03)00009-7","article-title":"A pilot trial of olanzapine for the treatment of cocaine dependence","volume":"70","author":"Kampman","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.genhosppsych.2023.05.003_bb0340","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1517\/14656560802694655","article-title":"Pharmacotherapy of patients with schizophrenia and substance abuse","volume":"10","author":"Wobrock","year":"2009","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.genhosppsych.2023.05.003_bb0345","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/WNF.0b013e3182908330","article-title":"Aripiprazole for treating cannabis-induced psychotic symptoms in ultrahigh-risk individuals","volume":"36","author":"Rolland","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"10.1016\/j.genhosppsych.2023.05.003_bb0350","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1017\/S1461145708009097","article-title":"Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers","volume":"11","author":"Newton","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2023.05.003_bb0355","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jsat.2007.01.008","article-title":"Substance abuse and schizophrenia: pharmacotherapeutic intervention","volume":"34","author":"Green","year":"2008","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"10.1016\/j.genhosppsych.2023.05.003_bb0360","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4088\/JCP.08r04171","article-title":"Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms","volume":"70","author":"Uchida","year":"2009","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.genhosppsych.2023.05.003_bb0365","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2165\/00002512-199813050-00003","article-title":"Drug dosage in the elderly. Is it rational?","volume":"13","author":"Turnheim","year":"1998","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.genhosppsych.2023.05.003_bb0370","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00004850-200015010-00002","article-title":"Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group","volume":"15","author":"Colonna","year":"2000","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.genhosppsych.2023.05.003_bb0375","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1176\/appi.ajp.161.1.139","article-title":"Comparisons of patients with comorbid psychiatric and substance use disorders: implications for treatment and service delivery","volume":"161","author":"Havassy","year":"2004","journal-title":"Am J Psychiatry"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834323000786?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834323000786?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:56:46Z","timestamp":1759013806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834323000786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":73,"alternative-id":["S0163834323000786"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2023.05.003","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2023.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}